Embryonic stem cell-derived cardiac myocytes are not ready for human trials.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 24935962.
- Also identified by DOI 10.1161/CIRCRESAHA.114.304616 and PMC identifier 4133694.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Recently a preclinical report assessed the efficacy, safety, and feasibility of using human embryonic stem cells to regenerate infarcted myocardium in a non-human primate model. This commentary evaluates that study by pointing out key weaknesses, offering an alternative perspective, and summarizing major unresolved issues. Our conclusion is that significant challenges remain before human embryonic stem cells are ready for use in clinical trials.
Medical subject headings
- Embryonic Stem Cells
- Heart
- Myocardial Infarction
- Myocytes, Cardiac
- Regeneration